LIFETECH SCI (01302) announced its annual results for the period ending December 31, 2025. The company reported revenue of RMB1.37 billion, representing an increase of approximately 5.1% compared to the previous year. However, profit attributable to shareholders was RMB148 million, a decrease of 33.53% year-on-year. Basic earnings per share stood at 3.4 fen. According to the announcement, the growth in revenue was primarily driven by increased sales of covered stents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.